<DOC>
	<DOCNO>NCT00000647</DOCNO>
	<brief_summary>To restore immunologic function virus-free state HIV-infected patient . Based previous study show temporary improvement immune function HIV-infected patient use peripheral lymphocyte transfer bone marrow transplantation , base study document antiretroviral effect zidovudine ( AZT ) interferon-alfa ( IFN-A ) well preliminary test tube patient study suggest anti-HIV effect recombinant CD4-IgG , propose treat HIV-infected patient use combination antiretroviral therapy transplantation bone marrow peripheral lymphocytes previously immunize donor attempt restore immunologic function virus-free state .</brief_summary>
	<brief_title>An Open Trial Combining Zidovudine , Interferon-alfa , Recombinant CD4-IgG With Transplantation Syngeneic Bone Marrow Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors Treatment Patients With HIV Infection</brief_title>
	<detailed_description>Based previous study show temporary improvement immune function HIV-infected patient use peripheral lymphocyte transfer bone marrow transplantation , base study document antiretroviral effect zidovudine ( AZT ) interferon-alfa ( IFN-A ) well preliminary test tube patient study suggest anti-HIV effect recombinant CD4-IgG , propose treat HIV-infected patient use combination antiretroviral therapy transplantation bone marrow peripheral lymphocytes previously immunize donor attempt restore immunologic function virus-free state . Three patient treat stable dos AZT , IFN-A , CD4-IgG 12 week , follow six peripheral lymphocyte infusion transplantation bone marrow respective identical twin . Following bone marrow transplantation , patient continue receive three drug . Additional period lymphocyte apheresis transfer may offer donor/recipient pair .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<criteria>Inclusion Criteria Each patient must identical twin normal state health normal screen lab panel normal immune profile document antibody culture polymerase chain reaction ( PCR ) negative HIV . Ability provide inform consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malignancy Kaposi 's sarcoma . Patients follow exclude : Unwillingness comply current NIH Clinical Center guideline concern appropriate notification current sexual partner individual regard positive HIV serostatus risk transmission HIV infection . Presence serious opportunistic infection illness condition , opinion principal investigator , warrant exclusion participation study . Current use illicit drug significant amount alcohol , opinion principal investigator , would interfere compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Carrier Proteins</keyword>
	<keyword>Interferon Type I</keyword>
</DOC>